Picture of Tourmaline Bio logo

TRML Tourmaline Bio Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Tourmaline Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-18.2-22.7-47.8-73.9-42.1
Depreciation
Non-Cash Items0.2011.434.9110.614.2
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.0851.612.311.1-0.168
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-17.7-19.2-40-60.9-28.1
Capital Expenditures-0.562-1.29-2.44-3.04-0.056
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0-132-9458.73.9
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-0.562-133-96.455.73.84
Financing Cash Flow Items-0.277064.8
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities36.21311370.242157
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash18-21.41.02-4.94132